Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin + anlotinib vs doxorubicin as first-line therapy for advanced L-type sarcoma
ChiCTR2600117706Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in leiomyosarcoma (LMS), Liposarcoma and soft tissue sarcoma (STS) comparing Doxorubicin monotherapy with Eribulin + anlotinib followed by anlotinib (2 arms). Primary endpoint: Median progression-free survival. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
eribulinanlotinibdoxorubicin
03
Conditions
leiomyosarcoma (LMS)Liposarcomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2600117706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117706.